Drug Trial Radar · NCT06499688
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
529
Actual
Start
Dec 28, 2023
Primary completion
Mar 29, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo- and active-controlled parallel-group multi-center phase III study to evaluate the efficacy and safety of Rcombinant botulinum neurotoxin type A for injection (YY001)) in the treatment of moderate to severe glabellar lines.
Conditions
- Moderate to Severe Glabellar Lines
Interventions
Rcombinant botulinum neurotoxin type A for injection (YY001)Biological
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
OnabotulinumtoxinABiological
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
PlaceboBiological
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The 4th week after treatment, the composite response rate on both the investigator's assessment and the participant's self-assessment concurrently of GL severity at maximal frown.Time frame: The 4th week after treatment
- At the 1st week, 8th week, and 12th week after treatment, the composite response rate on both the investigator's assessment and the participant's self- assessment concurrently of GL severity at maximal frown.Time frame: At the 1st week, 8th week, and 12th week after treatment
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital
Beijing, China
Peking Union Medical College Hospital , Chinese Academy of Medical Sciences
Beijing, China
Peking University First Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Plastic Surgery Hospital, Chinese Academy of Medical Science
Beijing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Tianjin Medical University General Hospital
Tianjin, China
Guangdong Second People's Hospital
Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
The Second Affiliated Hospital Of Xi'an Jiaotong University
Xian, Shanxi, China
West China School of Medicine/West China Hospital of Sichuan University
Chengdu, Sichuan, China
Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.